JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Does Preoperative Renal Tumour Biopsy Impact Trifecta Achievement in Partial Nephrectomy?

  • 0Department of Urology, Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
Aktuelle Urologie +

|

November 27, 2024

|

November 27, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Renal tumour biopsy (RTB) before open partial nephrectomy (OPN) did not affect trifecta criteria achievement. This study suggests RTB is safe for renal cancer patients undergoing OPN.

Area Of Science

  • Urology
  • Oncology
  • Surgical Pathology

Background

  • Open partial nephrectomy (OPN) is a standard treatment for renal cancer.
  • The trifecta criteria (negative margins, warm ischemia time <25 min, no complications) assess OPN outcomes.
  • The impact of pre-operative renal tumour biopsy (RTB) on trifecta achievement in OPN is not well-established.

Purpose Of The Study

  • To evaluate the effect of renal tumour biopsy (RTB) on trifecta criteria achievement in patients undergoing open partial nephrectomy (OPN).

Main Methods

  • Retrospective review of renal cancer patients undergoing OPN (2012-2023).
  • Comparison between patients who underwent RTB prior to OPN (RTB group) and those who did not (non-RTB group).
  • Primary outcome: trifecta achievement. Secondary outcomes: clinicopathologic and survival data.

Main Results

  • Trifecta achievement rates were similar between the RTB (53.3%) and non-RTB (54.76%) groups (p=0.878).
  • No significant differences in metastasis-free or overall survival at 24 months between groups.
  • Higher rates of intraparenchymal lymphovascular invasion were observed in the RTB group (16.6% vs 2.92%, p=0.013).

Conclusions

  • Renal tumour biopsy (RTB) does not negatively impact trifecta criteria achievement following open partial nephrectomy (OPN).
  • RTB can be safely incorporated into the management of renal cancer patients undergoing OPN.
  • Further investigation into the implications of lymphovascular invasion post-biopsy is warranted.